0120G0.KO Samyang Biopharm
- Market cap
- KRW 295B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0120G0.KO undervalued?
Graham numberThe Graham number of Samyang Biopharm cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Samyang Biopharm fundamental analysis
No fundamental analysis for Samyang Biopharm yet.
Samyang Biopharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Samyang Biopharm
Samyang Biopharm Corporation offers pharmaceutical and biotech products. The company was founded in 2011 and is based in Seoul, South Korea.
Full company profileFinancial statements of Samyang Biopharm are not available yet.
Samyang Biopharm dividends
Samyang Biopharm has not paid dividends in the last 1 fiscal years.
Who owns Samyang Biopharm
- Insiders 52.39%
- Institutions 3.86%
- Public & others 43.75%
- Shares outstanding 7.44M
Samyang Biopharm company profile
- Company name
- Samyang Biopharm
- Ticker
- 0120G0.KO
- ISIN
- KR70120G0001
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Address
- 263, Yeonji-dong, Seoul, South Korea, 110-470
- Website
- samyangbiopharm.com
About Samyang Biopharm
Samyang Biopharm Corporation offers pharmaceutical and biotech products. The company was founded in 2011 and is based in Seoul, South Korea.
Samyang Biopharm management
2- Dr. Kyeong-Jin KimPresident, CEO & Director · born 1963
- Dr. Hyun-Soo Lee Ph.D.Head of Management Support PU & Director